Suppr超能文献

左甲状腺素或碘治疗对地方性甲状腺肿患者甲状腺大小及甲状腺生长刺激免疫球蛋白的影响。

The effect of treatment with levothyroxine or iodine on thyroid size and thyroid growth stimulating immunoglobulins in endemic goitre patients.

作者信息

Wilders-Truschnig M M, Warnkross H, Leb G, Langsteger W, Eber O, Tiran A, Dobnig H, Passath A, Lanzer G, Drexhage H A

机构信息

Department of Medicine, Karl Franzens University, Graz, Austria.

出版信息

Clin Endocrinol (Oxf). 1993 Sep;39(3):281-6. doi: 10.1111/j.1365-2265.1993.tb02367.x.

Abstract

OBJECTIVE

We assessed the effect of levothyroxine or iodine on thyroid size and on thyroid growth stimulating immunoglobulins in endemic goitre patients.

DESIGN

Levothyroxine or iodine was given orally in an open randomized prospective study (100 and 200 micrograms respectively).

PATIENTS

Thirty-seven euthyroid patients with diffuse iodine deficiency goitres and thyroid growth stimulating immunoglobulins were studied.

MEASUREMENTS

Thyroid size, thyroid growth stimulating immunoglobulins (mitosis arrest assay), basal TSH, free T3, free T4, thyroid anti-microsomal antibodies, antithyroglobulin antibodies, anti-TSH receptor antibodies and urinary iodine excretion were measured.

RESULTS

Thyroid size decreased significantly in both groups, in the levothyroxine group more than in the iodine treated group. Thyroid growth stimulating immunoglobulins levels also decreased significantly in both groups. Between groups there was no statistically significant difference. A statistically significant correlation between thyroid growth stimulating immunoglobulins reduction profiles and goitre size reduction could not be established. TSH levels became suppressed in the levothyroxine group while the T4 values rose; in the iodine treated group TSH levels stayed constant as did T4. None of the patients developed thyroid microsomal or thyroglobulin auto-antibodies and/or hyperthyroidism during the treatment.

CONCLUSIONS

Levothyroxine as well as iodine was effective in reducing thyroid size as well as thyroid growth stimulating immunoglobulins levels in endemic goitre patients. Since in both groups TSH levels were not related to thyroid size reduction, other factors than TSH suppression must be responsible for the observed thyroid size reduction. Iodine itself by virtue of its antiproliferative action on thyrocytes may have had a direct action on the goitre reduction during iodine treatment; however, the levothyroxine dose, containing less iodine, had a similar effect. A complicated picture hence emerges with regard to factors involved in the shrinkage of iodine deficiency goitre during thyroxine or iodine therapy. These findings indicate that TSH and thyroid growth promoting immunoglobulins are not the only influences on the size of endemic goitres, although it cannot be excluded that these two factors contribute to influence the pathogenetic process.

摘要

目的

我们评估了左甲状腺素或碘对地方性甲状腺肿患者甲状腺大小及甲状腺生长刺激免疫球蛋白的影响。

设计

在一项开放性随机前瞻性研究中口服左甲状腺素或碘(分别为100微克和200微克)。

患者

研究了37例甲状腺功能正常、患有弥漫性碘缺乏性甲状腺肿且存在甲状腺生长刺激免疫球蛋白的患者。

测量指标

测量甲状腺大小、甲状腺生长刺激免疫球蛋白(有丝分裂阻滞试验)、基础促甲状腺激素(TSH)、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、甲状腺微粒体抗体、甲状腺球蛋白抗体、促甲状腺激素受体抗体及尿碘排泄量。

结果

两组患者的甲状腺大小均显著减小,左甲状腺素组减小程度大于碘治疗组。两组患者的甲状腺生长刺激免疫球蛋白水平也均显著降低。两组之间无统计学显著差异。无法确定甲状腺生长刺激免疫球蛋白降低情况与甲状腺肿大小减小之间存在统计学显著相关性。左甲状腺素组TSH水平被抑制,而T4值升高;碘治疗组TSH水平保持不变,T4值也如此。治疗期间无患者出现甲状腺微粒体或甲状腺球蛋白自身抗体和/或甲状腺功能亢进。

结论

左甲状腺素和碘均可有效减小地方性甲状腺肿患者的甲状腺大小及降低甲状腺生长刺激免疫球蛋白水平。由于两组的TSH水平均与甲状腺大小减小无关,因此除TSH抑制外,其他因素必定是观察到的甲状腺大小减小的原因。碘本身凭借其对甲状腺细胞的抗增殖作用,可能在碘治疗期间对甲状腺肿缩小产生了直接作用;然而,含碘量较少的左甲状腺素剂量也有类似效果。因此,在甲状腺素或碘治疗期间,碘缺乏性甲状腺肿缩小所涉及的因素呈现出复杂的情况。这些发现表明,TSH和促进甲状腺生长的免疫球蛋白并非影响地方性甲状腺肿大小的唯一因素,尽管不能排除这两个因素对发病过程有影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验